MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$22,427K
EPS
-$0.36
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
-
-
0*
-
Research and development
16,727
13,584
35,389*
17,938
General and administrative
7,135
8,188
11,629*
10,331
Total operating expenses
23,862
21,772
47,017*
28,269
Loss from operations
-23,862
-21,772
-47,017*
-28,269
Interest and other income (expense), net
1,491
1,732
2,590*
2,783
Interest expense
0
0
123*
815
Loss on extinguishment of debt (note 7)
-
-
-457*
-
Net loss
-22,371
-20,040
-45,007*
-26,301
Net unrealized loss on short-term investments
-56
-326
-84
35
Total other comprehensive loss
-
-
-84*
-
Comprehensive loss
-22,427
-20,366
-45,091
-26,266
Basic EPS
-0.36
-0.32
-0.735
-0.43
Diluted EPS
-0.36
-0.32
-0.735
-0.43
Basic Average Shares
61,919,233
61,803,467
61,308,003
61,406,475
Diluted Average Shares
61,919,233
61,803,467
61,308,003
61,406,475
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$22,427K
(48.40%↑ Y/Y)
Net loss
-$22,371K
(48.33%↑ Y/Y)
Net unrealized loss
on short-term...
-$56K
(65.00%↑ Y/Y)
Interest and other income
(expense), net
$1,491K
(-51.92%↓ Y/Y)
Loss from operations
-$23,862K
(47.66%↑ Y/Y)
Total operating
expenses
$23,862K
(-47.66%↓ Y/Y)
Research and development
$16,727K
(-48.05%↓ Y/Y)
General and
administrative
$7,135K
(-46.73%↓ Y/Y)
Buy us a coffee
PLIANT THERAPEUTICS, INC. (PLRX)
PLIANT THERAPEUTICS, INC. (PLRX)